This study plans to demonstrate the safety and efficacy of [68Ga]-DOTA-tyr3-Octreotide
([68Ga]-DOTATOC) as an accurate imaging technique for diagnosis, staging, and monitoring of
response to treatment in patients with Somatostatin receptor expressing tumors who undergo
imaging with a clinical indication. The investigators will conduct a study for 68Ga-DOTATOC
as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors.
68Ga-DOTATOC will be used in diagnostic assessment of patients with known or suspected NETs
for whom there is an appropriate standard clinical indication for 68Ga-DOTATOC PET/CT either
at staging or during follow up.